← Back to All US Stocks

BSPK Stock Analysis - Bespoke Extracts, Inc. AI Rating

BSPK OTC Pharmaceutical Preparations NV CIK: 0001409197
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2025-09-30
AI Rating
STRONG SELL
95% Confidence

📊 BSPK Key Takeaways

Revenue: $1.1M
Net Margin: -48.5%
Free Cash Flow: $-723.6K
Current Ratio: 0.11x
Debt/Equity: N/A
EPS: $-0.05
AI Rating: STRONG SELL with 95% confidence

Investment Thesis

Bespoke Extracts is in severe financial distress with negative stockholders' equity of -$2.6M, indicating liabilities exceed assets by a significant margin. Despite 42.3% revenue growth, the company is deeply unprofitable with a -48.5% net margin, burning cash at an alarming rate (-$723.6K free cash flow) while maintaining minimal liquidity (0.11x current ratio). The combination of deteriorating financial position, negative equity, and unsustainable cash burn presents an extreme capital structure risk.

BSPK Strengths

  • + Revenue growth of 42.3% year-over-year demonstrates market traction
  • + Gross margin of 48.4% suggests underlying product economics are viable
  • + Some improvement in diluted EPS despite continued losses

BSPK Risks

  • ! Negative stockholders' equity of -$2.6M indicates insolvency risk and potential total loss for equity holders
  • ! Critically low liquidity ratios (0.11x current ratio, 0.07x quick ratio) with only $16.7K cash against $2.9M liabilities
  • ! Severe cash burn with -$123.6K operating cash flow and -$723.6K free cash flow unsustainable without immediate capital injection
  • ! Operating margin of -41.1% with $461.2K operating loss shows inability to scale profitably
  • ! High capex of $600K relative to $1.1M revenue suggests investment-phase company without path to profitability

Key Metrics to Watch

BSPK Financial Metrics

Revenue
$1.1M
Net Income
$-543.7K
EPS (Diluted)
$-0.05
Free Cash Flow
$-723.6K
Total Assets
$295.6K
Cash Position
$16.7K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BSPK Profitability Ratios

Gross Margin 48.4%
Operating Margin -41.1%
Net Margin -48.5%
ROE N/A
ROA -184.0%
FCF Margin -64.5%

BSPK vs Healthcare Sector

How Bespoke Extracts, Inc. compares to Healthcare sector averages

Net Margin
BSPK -48.5%
vs
Sector Avg 12.0%
BSPK Sector
ROE
BSPK 0.0%
vs
Sector Avg 15.0%
BSPK Sector
Current Ratio
BSPK 0.1x
vs
Sector Avg 2.0x
BSPK Sector
Debt/Equity
BSPK 0.0x
vs
Sector Avg 0.6x
BSPK Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BSPK Balance Sheet & Liquidity

Current Ratio
0.11x
Quick Ratio
0.07x
Debt/Equity
N/A
Debt/Assets
978.1%
Interest Coverage
-36.39x
Long-term Debt
N/A

BSPK 5-Year Financial Trend

BSPK 5-year financial data: Year 2018: Revenue $15.9K, Net Income N/A, EPS N/A. Year 2019: Revenue $62.1K, Net Income N/A, EPS $-0.21. Year 2022: Revenue $35.6K, Net Income -$965.6K, EPS $-0.19. Year 2023: Revenue $785.5K, Net Income -$4.1M, EPS $-0.44. Year 2024: Revenue $1.1M, Net Income -$1.5M, EPS $-0.15.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Bespoke Extracts, Inc.'s revenue has grown significantly by 6,920% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.15 indicates the company is currently unprofitable.

BSPK Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-64.5%
Free cash flow / Revenue

BSPK Quarterly Performance

Quarterly financial performance data for Bespoke Extracts, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $277.5K -$78.1K $-0.01
Q2 2025 $278.2K -$205.1K $-0.02
Q1 2025 $260.4K -$260.5K $-0.02
Q3 2024 $244.4K -$275.6K $-0.03
Q2 2024 $188.2K -$260.9K $-0.03
Q1 2024 $89.0K -$314.1K $-0.03
Q3 2023 $3.4K -$301.5K $-0.01
Q2 2023 $346 -$464.9K $-0.05

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

BSPK Capital Allocation

Operating Cash Flow
-$123.6K
Cash generated from operations
Stock Buybacks
$27.5K
Shares repurchased (TTM)
Capital Expenditures
$600.0K
Investment in assets
Dividends
None
No dividend program

BSPK SEC Filings

Access official SEC EDGAR filings for Bespoke Extracts, Inc. (CIK: 0001409197)

📋 Recent SEC Filings

Date Form Document Action
Jan 8, 2026 4 xslF345X05/ownership.xml View →
Nov 19, 2025 8-K ea0266433-8k_bespoke.htm View →
Nov 12, 2025 10-Q ea0261159-10q_bespoke.htm View →
Oct 8, 2025 8-K ea0260714-8k_bespoke.htm View →
Sep 11, 2025 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about BSPK

What is the AI rating for BSPK?

Bespoke Extracts, Inc. (BSPK) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BSPK's key strengths?

Revenue growth of 42.3% year-over-year demonstrates market traction. Gross margin of 48.4% suggests underlying product economics are viable.

What are the risks of investing in BSPK?

Negative stockholders' equity of -$2.6M indicates insolvency risk and potential total loss for equity holders. Critically low liquidity ratios (0.11x current ratio, 0.07x quick ratio) with only $16.7K cash against $2.9M liabilities.

What is BSPK's revenue and growth?

Bespoke Extracts, Inc. reported revenue of $1.1M.

Does BSPK pay dividends?

Bespoke Extracts, Inc. does not currently pay dividends.

Where can I find BSPK SEC filings?

Official SEC filings for Bespoke Extracts, Inc. (CIK: 0001409197) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BSPK's EPS?

Bespoke Extracts, Inc. has a diluted EPS of $-0.05.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2025-09-30 | Powered by Claude AI